Literature DB >> 15448920

[Why do schizophrenic patients smoke?].

K Cattapan-Ludewig1, S Ludewig, E Jaquenoud Sirot, M Etzensberger, F Hasler.   

Abstract

Patients suffering from schizophrenia are known to show an increased prevalence of nicotine addiction. The aim of this paper is to elucidate the relationship between schizophrenia and (chronic) use of nicotine. Nicotine seems to improve cognitive functions critically affected in schizophrenia, in particular sustained attention, focused attention, working memory, short-term memory, and recognition memory. Furthermore, several studies using evoked potentials (P50 paradigm) and prepulse inhibition of the acoustic startle reflex suggest that deficient preattentive information processing, a core feature of schizophrenia illness, is improved following treatment with nicotine. Smoking can also improve extrapyramidal secondary effects of antipsychotic medication and it induces cytochrome P4501A2, an enzyme system involved in the metabolism of several antipsychotics. There is substantial evidence that nicotine could be used by patients with schizophrenia as a "self-medication" to improve deficits in attention, cognition, and information processing and to reduce side effects of antipsychotic medication. Possible pharmacotherapeutic approaches for the regulation of abnormal neurotransmission at nicotinic acetylcholine receptors are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15448920     DOI: 10.1007/s00115-004-1818-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  73 in total

1.  Effect of acute subcutaneous nicotine on prepulse inhibition of the acoustic startle reflex in healthy male non-smokers.

Authors:  V Kumari; P A Cotter; S A Checkley; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1997-08       Impact factor: 4.530

2.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.

Authors:  Robert W Buchanan; Ann Summerfelt; Cenk Tek; James Gold
Journal:  Schizophr Res       Date:  2003-01-01       Impact factor: 4.939

3.  Smoking and schizophrenia: abnormal nicotinic receptor expression.

Authors:  S Leonard; C Breese; C Adams; K Benhammou; J Gault; K Stevens; M Lee; L Adler; A Olincy; R Ross; R Freedman
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

4.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

5.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

Authors:  A Olincy; D A Young; R Freedman
Journal:  Biol Psychiatry       Date:  1997-07-01       Impact factor: 13.382

6.  Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro.

Authors:  C Vidal; J P Changeux
Journal:  Neuroscience       Date:  1993-09       Impact factor: 3.590

Review 7.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

8.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

9.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 10.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

View more
  1 in total

1.  [Substance use associated disorders: frequency in patients with schizophrenic and affective psychoses].

Authors:  L Hermle; R Szlak-Rubin; K L Täschner; P Peukert; A Batra
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.